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Pathogenic bacteria are armed with potent effector proteins that subvert host 26 
signaling processes during infection1. The activities of bacterial effectors and 27 
their associated roles within the host cell are often poorly understood, 28 
particularly for Chlamydia trachomatis2, a WHO-designated neglected disease 29 
pathogen. We identify and explain remarkable dual Lys63-deubiquitinase (DUB) 30 
and Lys-acetyltransferase (AcT) activities in the Chlamydia effector ChlaDUB1. 31 
Crystal structures capturing intermediate stages of each reaction reveal how 32 
the same catalytic center of ChlaDUB1 can facilitate such distinct processes, 33 
and enable the generation of mutations that uncouple the two activities. 34 
Targeted Chlamydia mutant strains allow us to link the DUB activity of 35 
ChlaDUB1 and of the related, dedicated DUB ChlaDUB2 to fragmentation of the 36 
host Golgi apparatus, a key process in Chlamydia infection for which effectors 37 
have remained elusive. Our work illustrates the incredible versatility of 38 
bacterial effector proteins, and provides important insights toward 39 
understanding Chlamydia pathogenesis. 40 
 41 
During infection, many Gram-negative pathogenic bacteria translocate effector 42 
proteins directly into host cells to modify signaling pathways important for invasion, 43 
survival, and replication. One particularly interesting family of effectors are those 44 
belonging to the CE clan of cysteine proteases. Members of this family were 45 
variously found to be proteases for ubiquitin-like (Ubl) modifiers, deubiquitinases 46 
(DUBs), or even Ser/Thr acetyltransferases (AcTs)3,4,5,6,7,8,9,10,11, which is striking 47 
considering that they all share a structurally similar Cys protease fold. 48 
Physiologically, the activities are used against host inflammatory pathways. 49 
Deubiquitinases in particular are used by a wide range of pathogens to switch off 50 
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ubiquitin (Ub)-dependent inflammatory signaling processes12, or interfere with 51 
microbe-directed autophagy (xenophagy) pathways. CE family DUBs such as 52 
Legionella SidE, Salmonella SseL, or Chlamydia ChlaDUB1 have been shown to 53 
mediate inhibition of autophagy, NF-κB signaling or cell death, during 54 
infection10,13,14,15. Similarly, the AcT activities of Yersinia YopJ and Salmonella AvrA 55 
modify phosphorylation sites, and directly block MAP kinase activation required for 56 
inflammatory signaling and innate immunity7,8,9. 57 
 58 
Recent phylogenetic analyses and crystal structures have started to explain the 59 
seemingly disconnected catalytic activities among CE family members, but the 60 
conundrum of the identical catalytic fold has remained intriguing. Indeed, a direct 61 
biochemical comparison of DUB and AcT activities in CE family proteins has not yet 62 
been performed. We used our panel of purified bacterial CE enzymes from a range of 63 
pathogens alongside their catalytically inactive variants (Fig. 1a) to test for DUB 64 
activity by monitoring cleavage of K63-linked diUb (Fig. 1b). In parallel, we tested for 65 
AcT activity by monitoring auto-acetylation via radioisotope incorporation following 66 
incubation with 14C Acetyl-Coenzyme A (Fig. 1c). This analysis revealed Salmonella 67 
SseL, Escherichia ElaD, Shigella ShiCE, and Rickettsia RickCE to be dedicated 68 
DUBs, and identified Legionella LegCE, Yersinia YopJ, and Salmonella AvrA to be 69 
dedicated AcTs.  70 
 71 
Remarkably, Chlamydia ChlaDUB1 could perform both DUB and AcT reactions, 72 
seemingly using the same catalytic Cys residue (compare Fig. 1, b and c). 73 
ChlaDUB1 is phylogenetically distinct from the YopJ-like family11, but showed similar 74 
rates of auto-acetylation compared to YopJ and AvrA (although YopJ acetylation of 75 
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its substrate MEK2 (ref. 8) is markedly faster, see Supplementary Fig. 1a,b,c). 76 
Importantly, ChlaDUB1 auto-acetylation occurs at Lys residues (Supplementary Fig. 77 
1d,e) whereas YopJ-like family members predominantly target Ser/Thr residues7,8,9. 78 
Furthermore, ChlaDUB1 AcT activity is not regulated by phytic acid (inositol 79 
hexakisphosphate, IP6) (Supplementary Fig. 1f,g), in contrast to YopJ-like 80 
enzymes16,17. This identified ChlaDUB1 as a bona-fide Lys-AcT in addition to being a 81 
Lys63-specific DUB.  82 
 83 
To explain how ChlaDUB1 could perform two seemingly disparate chemical 84 
reactions, namely deubiquitination – a hydrolysis reaction, and acetylation – a 85 
condensation reaction, we determined crystal structures of the enzyme bound to Ub, 86 
and bound to Coenzyme A (CoA) at 1.9 Å and 2.1 Å resolution, respectively (Fig. 1d 87 
and Supplementary Table 1). The structures showed hardly any conformational 88 
changes between each other, or in comparison to previous apo structures (pdb-id 89 
5HAG11, 5B5Q15) with overall RMSDs <1 Å (Fig. 1e and Supplementary Fig. 2a), 90 
but revealed distinct binding sites for Ub and CoA.  91 
 92 
The ChlaDUB1~Ub structure (Supplementary Fig. 2b) was obtained using the Ub 93 
activity based probe Ub-propargylamide (UbPA), which covalently links one Ub 94 
molecule into the enzymatic S1 site (Supplementary Fig. 3). ChlaDUB1 forms 95 
similar interactions with Ub as compared to other CE proteases10,11,18,19,20, involving 96 
both the Ile44 and Ile36 hydrophobic patches of Ub (Supplementary Fig. 2c,d).  97 
 98 
The ChlaDUB1~CoA structure (Supplementary Fig. 2e) revealed a disulfide bridge 99 
between the cofactor’s cysteamine and the catalytic Cys, and identified a charge-100 
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complementary binding site for CoA near the active site (Supplementary Fig. 2f). 101 
The ChlaDUB1 CoA binding site is distinct from the CoA binding sites of the YopJ-102 
like effector HopZ1a16 and arylamine N-acetyltransferases (NATs)21 (Supplementary 103 
Fig. 2g,h), and also removed from the Ub binding site (Supplementary Fig. 3). 104 
 105 
Both structures together reveal the importance of an inserted helix that is unique to 106 
ChlaDUB1 and not present in other CE enzymes from bacteria, viruses, or 107 
eukaryotes; we had previously annotated this element as Variable Region 3 (VR-3)11. 108 
One face of this VR-3 helix contacts the adenosine and phosphate groups of the CoA 109 
molecule (Fig. 2a,b). Remarkably, the opposite face of the VR-3 helix binds the 110 
Ile36-patch of Ub (Fig. 2a,b, Supplementary Fig. 2i). This arrangement enables 111 
both DUB and AcT activities to utilize the same active site (Fig. 1d and 112 
Supplementary Fig. 4a,b), via spatially separated, independent binding sites for Ub 113 
and CoA. Consistently, Ub compromises AcT activity, but when the Ub C-terminus is 114 
missing, auto-acetylation is restored (Supplementary Fig. 4c). Separate binding 115 
sites for Ub and CoA further enabled us to uncouple DUB and AcT activity. 116 
ChlaDUB1 AcT activity was strongly diminished by mutation of K268E (VR-3), or 117 
G272E without affecting DUB activity. In contrast, DUB activity was abrogated by 118 
I267R (VR-3) or I225A mutation, yet these mutants did not affect auto-acetylation 119 
(Fig. 2a,c, and Supplementary Fig. 5a).  120 
 121 
The VR-3 helix is central to dual activities in C. trachomatis (C.t.) ChlaDUB1 and 122 
present in all Chlamydia ChlaDUB homologues, such as ChlaDUB of C. abortus 123 
(C.a.), a cattle pathogen that is transmissible to humans. A 1.5 Å crystal structure of 124 
C.a. ChlaDUB confirmed the register of the predicted VR-3 helix as shown in the 125 
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sequence alignment (Fig. 2d, Supplementary Fig. 5d,e, and Supplementary Table 126 
1). Importantly, the Ub- and CoA-coordinating residues within VR-3 are not jointly 127 
conserved (Fig. 2d), and we hypothesized that C.t. ChlaDUB2 should be a dedicated 128 
DUB, while C.a. ChlaDUB should be a dedicated AcT. Indeed, these predictions 129 
could be confirmed biochemically (Fig. 2e,f and Supplementary Fig. 5b,c). 130 
Together, our data strongly suggested that Chlamydia species evolved ChlaDUB 131 
effectors with dual activities and potentially multiple functions.  132 
 133 
Functional characterization of Chlamydia effectors has remained challenging, mostly 134 
due to the rudimentary tools available for genetic manipulation of Chlamydia22. 135 
Nonetheless, we set out to uncover roles for the DUB/AcT ChlaDUB1 and the 136 
dedicated DUB ChlaDUB2 utilizing mutant strains harboring catalytically inactive 137 
ChlaDUB1 and ChlaDUB2 variants. One strain, containing a mutation leading to an 138 
amino acid substitution in the ChlaDUB2 catalytic His residue (H203Y) that 139 
inactivates the enzyme (Supplementary Fig. 6a), was identified from a collection of 140 
chemically mutagenized C. trachomatis strains23. This strain was back-crossed to 141 
wild-type C. trachomatis and a clean recombinant strain harboring only the 142 
ChlaDUB2 H203Y variant was isolated (Cdu2-H203Y) (Fig. 3a, Supplementary 143 
Table 2, 3). For ChlaDUB1, we obtained a recently characterized ChlaDUB1 mutant 144 
strain15 generated by transposon mutagenesis that introduced an early stop codon 145 
before the catalytic Cys residue (cdu1-Tn) (Fig. 3a, Supplementary Table 2). 146 
 147 
The ChlaDUB1 and ChlaDUB2 loss of function strains left us in the privileged 148 
position to assess the effects of either enzyme on host biology, and on contributions 149 
to Chlamydia infection. The cdu1-Tn mutant strain did not significantly reduce the 150 
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number of infectious progeny in HeLa cells as compared to a wild-type strain. This 151 
was markedly different in A549 cells, a human adenocarcinomic lung epithelial cell 152 
line, in which infection with the cdu1-Tn mutant strain reduced progeny by 90% (Fig. 153 
3b). The latter was comparable to the effect of this strain in vivo using a transcervical 154 
mouse model of infection, whereas primary human fimbriae cells showed a bacterial 155 
growth defect only after prior stimulation with interferon-γ15. Surprisingly, the Cdu2-156 
H203Y strain showed little to no growth defect in either HeLa or A549 cell lines 157 
compared to its two parental strains (see Methods) (Fig. 3b), suggesting that 158 
ChlaDUB1, with its additional AcT activity, may play a unique role in Chlamydia 159 
infection.  160 
 161 
Next, we inspected infected cells by confocal microscopy. A prominent feature of 162 
Chlamydia-infected cells is the fragmentation and subsequent redistribution of the 163 
Golgi apparatus into ministacks that surround the pathogen-containing vacuole 164 
(termed the inclusion) at approximately 20 hours post infection24,25. Because 165 
ChlaDUB1 and ChlaDUB2 are actively expressed and secreted at this time post 166 
infection and have been shown to localize to the outside of the inclusion membrane 167 
where they could interact with neighboring organelles15,28, we used our cdu1-Tn and 168 
Cdu2-H203Y mutant strains to test for a contribution to Golgi redistribution following 169 
infection. Remarkably, at 26-hours post infection, both the cdu1-Tn and Cdu2-H203Y 170 
mutant strains showed a dramatic impairment in redistribution of the Golgi apparatus 171 
(Fig. 3c-f and Supplementary Fig. 6b-e). Since both ChlaDUB1 and ChlaDUB2 172 
mutant strains affected host Golgi redistribution, this strongly suggested that DUB 173 
activity is required in this process. Moreover, the comparable individual impact of 174 
each mutant strain on Golgi redistribution (Fig. 3e,f) indicates either non-redundant 175 
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roles for each DUB, or a strict dose dependency on DUB-activity introduced by 176 
Chlamydia to invoke the observed cell biological effect. Finally, a similar extent of 177 
Golgi redistribution was seen in A549 but also HeLa cells, contrasting the different 178 
impact of ChlaDUB mutant strains on bacterial growth rates (compare Fig. 3c-f with 179 
3b). This lack of correlation had been observed previously in HeLa cells, e.g. with 180 
InaC that regulates Golgi redistribution without impacting generation of bacterial 181 
progeny23.  182 
 183 
Our data suggested that ChlaDUB1 and ChlaDUB2 may have unrecognized roles in 184 
manipulating Golgi morphology and dynamics, which was corroborated in a simplified 185 
system (Fig. 4a). Strikingly, we found that Golgi fragmentation was readily induced 186 
by sole expression of either ChlaDUB1 or ChlaDUB2 in HeLa cells (Fig. 4b, 187 
Supplementary Fig. 7a,b, and Supplementary Fig. 8a,b). Expression of wild-type 188 
ChlaDUB1 and (to a lesser extent) ChlaDUB2 resulted in significant Golgi 189 
fragmentation as measured either by the number or the size of Golgi-stained puncta. 190 
Importantly, active site mutations eliminated this effect, which was again more 191 
pronounced for ChlaDUB1 (Fig. 4c,d, Supplementary Fig. 7c,d, and 192 
Supplementary Fig. 8c,d). All ChlaDUB1 constructs showed an enriched 193 
localization to the Golgi apparatus, indicating that the introduced mutations 194 
exclusively affect activity (Fig 4b, Supplementary Fig. 7b). ChlaDUB2 appeared to 195 
primarily localize to the endoplasmic reticulum (Supplementary Fig. 8e), which 196 
could explain its reduced ability to induce Golgi fragmentation as compared to 197 
ChlaDUB1. Using our structure-guided mutations that separate ChlaDUB1 DUB and 198 
AcT function (Fig. 2g and 4a), the Golgi fragmentation could be assigned as a DUB-199 
dependent effect: A DUB-deficient I267R mutant was as defective in Golgi 200 
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fragmentation as a catalytically-inactive C345A construct, while an AcT-deficient 201 
ChlaDUB1 K268E mutant retained its Golgi fragmenting capabilities (Fig. 4b-d and 202 
Supplementary Fig. 7a-d).   203 
 204 
Together, we here unveil a remarkable case of protein moonlighting29, wherein a 205 
bacterial effector, C. trachomatis ChlaDUB1, performs two distinct enzymatic 206 
activities within its catalytic site, leading to separable cellular functions. Single amino 207 
acid substitutions can toggle between the activities, and this is used by closely 208 
related orthologues and paralogues in this enzyme family to modulate function (Fig. 209 
2g). We further establish that the DUB activities present in ChlaDUB1 and also in the 210 
dedicated DUB paralogue ChlaDUB2, are necessary and sufficient for the 211 
fragmentation of the host Golgi apparatus, a prerequisite to Golgi redistribution 212 
around the Chlamydia inclusion. This adds ChlaDUB1 and ChlaDUB2 to the limited 213 
list of effectors and host factors implicated in this striking cell biological 214 
phenomenon23-27 (see Supplementary Fig. 9). In overexpression studies, ChlaDUB1 215 
has also been implicated with inhibition of NF-κB signaling13 and cell death15, and it 216 
is tempting to speculate that some of these effects are conferred by the AcT activity 217 
of ChlaDUB1. While this requires further study, the importance of ChlaDUB1 for 218 
Chlamydia infectivity15 and its unique enzymatic nature make it an interesting 219 
candidate for future Chlamydia-targeted therapeutics. 220 
  221 
 10 
Methods 222 
Cloning and molecular biology. Generation of Salmonella Typhimurium SseL, 223 
Chlamydia trachomatis ChlaDUB1, Escherichia coli ElaD, Shigella flexneri ShiCE, 224 
Rickettsia bellii RickCE, Legionella pneumophila LegCE, Yersinia pestis YopJ, and 225 
Salmonella Typhimurium AvrA constructs was described previously11. Sequences for 226 
Chlamydia trachomatis ChlaDUB2 and Chlamydia abortus ChlaDUB were obtained 227 
via gene synthesis (Life Technologies). Following amplification with KOD polymerase 228 
(EMD Millipore), the genes were inserted into the pOPIN-B or pOPIN-GFP vector30 229 
with the In-Fusion cloning method (Takara Bio USA). All mutagenesis was performed 230 
using the Quikchange method (Agilent). 231 
 232 
Protein expression and purification. Expression and purification of SseL (24-340), 233 
ElaD (2-407), ShiCE (2-405), RickCE (378-691), LegCE (141-360), YopJ (1-288), 234 
and AvrA (1-288) has been described previously11. C.t. ChlaDUB1 (130-401), C.t. 235 
ChlaDUB2 (80-339), and C.a. ChlaDUB were expressed in E. coli Rosetta2 pLacI 236 
cells (Novagen) at 18˚C for 20 h following induction with 0.2 mM IPTG an OD600 of 237 
0.8-1.0. Cells were harvested in 25 mM Tris (pH 7.4), 200 mM NaCl, 2 mM ß-238 
mercaptoethanol (Buffer A) and subjected to one freeze-thaw cycle. EDTA-free 239 
Complete protease inhibitor tablets (Roche), DNase, and Lysozyme were added prior 240 
to lysis by sonication. The resulting lysate was centrifuged at 35000 x g for 25 min, 241 
and applied to Talon resin (Takara Bio USA). The resin was washed with Buffer A 242 
thoroughly prior to elution with Buffer A containing 250 mM imidazole. During 243 
overnight dialysis back to Buffer A at 4˚C, the His-tag was cleaved with His-3C 244 
protease. Following a reverse affinity step over regenerated Talon resin, the resulting 245 
protein was then concentrated (10,000 MWCO, EMD Millipore) and applied to a gel 246 
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filtration column (Superdex75, GE Healthcare) equilibrated in 25 mM HEPES (pH 247 
8.0), 150 mM NaCl, 5 mM DTT. Pure protein-containing fractions were concentrated, 248 
aliquoted, and flash-frozen for storage at -80˚C. 249 
 250 
Deubiquitinase assays. All enzymes were diluted to a ‘2x’ concentration in 25 mM 251 
Tris (pH 7.4), 150 mM NaCl, 10 mM DTT and allowed to fully reduce for 20 min at 252 
room temperature. 6 µM diUb stocks were prepared in 100 mM Tris (pH 7.4), 100 253 
mM NaCl, 10 mM DTT and mixed 1:1 with 2x enzyme prior to incubation at 37˚C. 254 
Samples were quenched in reducing LDS sample buffer (ThermoFisher), resolved by 255 
SDS-PAGE, and visualized using silver stain (BioRad). 256 
Ub/Ubl KG-TAMRA protease assays were performed as described previously11. 257 
 258 
Acetylation assays. All enzymes were diluted to 5 µM in 25 mM HEPES (pH 8.0), 259 
50 mM NaCl, 0.5 mM DTT and incubated with 60 µM [1-14C] Acetyl-CoA (60 260 
mCi/mmol, PerkinElmer) at 37˚C for the indicated time. The panel shown in Figure 1 261 
and all subsequent assays with YopJ or AvrA additionally included 200 nM inositol 262 
hexakisphosphate (IP6). Reactions were quenched with reducing LDS sample buffer 263 
(ThermoFisher) and resolved by SDS-PAGE prior to staining with Coomassie. Gels 264 
were then dried and exposed to a Phosphor screen for several days prior to imaging 265 
on a Typhoon scanner (GE Healthcare). 14C autoradiography intensity was quantified 266 
using ImageJ31 and normalized to the Coomassie stain signal. 267 
 268 
Protein crystallization. The ChlaDUB1 (130-401)~Ub complex was purified by gel 269 
filtration following an overnight reaction at room temperature with 2-fold molar excess 270 
Ub-PA suicide probe32. Native ChlaDUB1~Ub crystals were obtained using protein 271 
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prepared in 25 mM Tris (pH 7.4), 125 mM NaCl, 4 mM DTT and crystallized at 10 272 
mg/mL in 0.1 M MES (pH 6), 20% PEG 6000, with a 400 nL sitting drop at 1:1 273 
protein:precipitant ratio. SeMet ChlaDUB1~Ub crystals were obtained using protein 274 
at 7 mg/mL in 0.1 M HEPES (pH 7.1), 18% PEG 8K, with a 200 nL sitting drop at 1:1 275 
protein:precipitant ratio. The ChlaDUB1~CoA complex was crystallized by addition of 276 
2 mM CoA to 12 mg/mL ChlaDUB1, and mixing with 0.1 M HEPES (pH 7.2), 20% 277 
PEG 8000 at a 1:1 protein:precipitant ratio in a 400 nL sitting drop. C. a. ChlaDUB 278 
(108-377) was prepared in 25 mM HEPES (pH 8.0), 150 mM NaCl, 5 mM DTT and 279 
crystallized in 0.1 M Tris (pH 7), 0.2 M calcium acetate, 20% PEG 3000 with a 400 nL 280 
sitting drop at 1:1 protein:precipitant ratio. All crystals were cryoprotected with mother 281 
liquor containing 25% glycerol. Cryoprotectant for ChlaDUB1~CoA crystals also 282 
contained 5 mM CoA. 283 
 284 
Data collection, structure determination, and refinement. Data were collected at 285 
100K at the Diamond Light Source (DLS) beam lines I02, I03, and I04 (see 286 
Supplementary Table 1). Data collections were performed at 0.9798, 0.9795, and 287 
0.9794 Å wavelength for the ChlaDUB1~Ub, ChlaDUB1~CoA, and C.a. ChlaDUB 288 
structures, respectively. Integration and scaling were performed using XDS33 and 289 
Aimless34, respectively. The ChlaDUB1~Ub structure was solved experimentally 290 
using a SeMet SAD dataset with PHENIX AutoSol and AutoBuild35.36,37. 291 
ChlaDUB1~CoA and C.a. ChlaDUB structures were solved using molecular 292 
replacement in Phaser38 using the apo ChlaDUB1 structure (pdb id 5HAG). Iterative 293 
rounds of model building and refinement were performed using COOT39 and 294 
PHENIX35, respectively. Ramachandran statistics (favored/allowed/outliers) for the 295 
ChlaDUB1~Ub, ChlaDUB1~CoA, and C.a. ChlaDUB structures were 97.2/2.8/0, 296 
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97.4/2.6/0, and 98.0/2.0/0, respectively. All figures were generated using PyMOL 297 
(www.pymol.org). 298 
 299 
Cell lines. HeLa, A549, and Vero cell lines were obtained from ATCC, where they 300 
were authenticated by morphology, karyotyping, and STR analyses. Stocks were 301 
routinely tested and confirmed negative for mycoplasma contamination. 302 
 303 
Chlamydia growth conditions and infections. HeLa, A549, and Vero cells were 304 
grown in high glucose DMEM supplemented with L-glutamine, sodium pyruvate 305 
(Gibco, Life Technologies) and 10% FBS (Mediatech, CellGro), at 37 ºC in a 5% CO2 306 
humidified incubator. All cells infected with Chlamydia were centrifuged at 3,500 rpm 307 
for half an hour at 10°C immediately upon infection. 308 
 309 
Chlamydia strains. All Chlamydia strains (Supplementary Table 2) were derived 310 
from C. trachomatis LGV biovar L2 434/Bu (wild-type). The cdu1-Tn strain was 311 
generously provided by Scott Hefty (The University of Kansas) and described 312 
previously15. The cdu2-G607A (Cdu2-H203Y) allele was identified in a collection of 313 
chemically mutagenized C. trachomatis L2 434/Bu strains by whole genome 314 
sequencing of a collection of pooled mutant strains23. Strain CTL2M467 was 315 
identified to harbor the cdu2-G607A single nucleotide variant (SNV) by Sanger 316 
sequencing of the cdu2 (CTL0246) locus. Vero cells seeded in a 6 well plate were 317 
infected with CTL2M467. At 48 hours post infection (hpi), cell monolayers were lysed 318 
by hypotonic lysis, lysates sonicated, and bacterial cells collected by centrifugation at 319 
14,000 rpm for 15 minutes at 4 °C. Bacterial cell pellets were resuspended in 1X 320 
DNAse I buffer (New England Biolabs) and treated with 4 Units of DNAse 1 (New 321 
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England Biolabs) for 1 hour at 37 °C to deplete co-purifying Vero DNA. Following a 322 
wash with PBS buffer, total DNA was isolated with a DNA isolation kit (DNeasy tissue 323 
and blood kit, Qiagen, Valencia, CA) following the manufacturer’s instructions.  324 
One µg of CTL2M467 enriched DNA was fragmented with NEBNext dsDNA 325 
Fragmentase (New England Biolabs) and DNA sequencing libraries prepared with a 326 
NEBnext DNA Library Prep Kit for Illumina according to manufacturer’s instructions. 327 
Libraries were sequenced with the MiSeq DNA Sequencing Platform (Illumina, Inc. 328 
San Diego, CA) at the Duke University IGSP sequencing facility. Genome assembly 329 
and single nucleotide variant (SNV) identification was performed with Geneious 330 
version 6 (Biomatters, http://www.geneious.com/). The C. trachomatis L2 434/Bu 331 
genome (GenBank no. NC_010287) was used as reference sequence. All SNV’s 332 
identified (Supplementary Table 3) were independently verified by Sanger 333 
sequencing. M467 rs22 was isolated from a backcross of parental strain CTL2M467 334 
(rifampin resistant-RifR) with a spectinomycin resistant L2 434/Bu strain (SpecR) as 335 
described previously40. Vero cells were co-infected with strains CTL2M467 (RifR) and 336 
L2 434/Bu (SpecR) at an MOI of 3 and a ratio of 1:1. At 48 hpi, crude cell lysates 337 
prepared in SPG buffer (0.25 M sucrose, 10 mM sodium phosphate, 5 nM glutamic 338 
acid) were used to infect Vero cells seeded in a 6 well plate. At 2 hpi, an 339 
agarose/DMEM overlay supplemented with rifampin (200 ng/mL) and spectinomycin 340 
(200 µg/mL) was added to infected cells as previously described40 and cells 341 
incubated for 14 days. Recombinant strains were isolated from twenty-four individual 342 
plaques and expanded in Vero cells. All recombinant strains were genotyped by PCR 343 
for presence of CTL2M467 parental non-synonymous SNVs (Supplementary Table 344 
3). Recombinant strain number 22 (M467 rs22) was found to harbor only the parental 345 
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cdu2-G607A mutation (Cdu2-H203Y). Chlamydia strains were maintained as frozen 346 
stocks in SPG buffer.  347 
 348 
Chlamydia growth assays. HeLa and A549 cells were seeded in wells of two 96 349 
well plates (input and output plates). Cells were infected with Chlamydia strains at an 350 
MOI of 0.6. At 24 hpi, infected cells in input plate were fixed with ice cold Methanol 351 
and stored in PBS. At 48 hpi, crude lysates in SPG were prepared from infected cells 352 
in output plates and a series of 1/10 dilutions were used to immediately infect 353 
corresponding HeLa or A549 cells seeded in wells of a 96 well plate. At 24 hpi, cells 354 
were fixed with ice cold Methanol. Fixed cells were stained with rabbit anti-Slc141 and 355 
Hoechst. Images from stained cells were captured on an EVOS cell imaging system 356 
(ThermoFisher scientific) with a 20X objective. Inclusion forming units (IFUs) were 357 
quantified using Image J (NIH). Output IFU’s from each Chlamydia inoculum was 358 
normalized to their respective input IFU’s. Chlamydia IFU production was measured 359 
from 3 independent biological replicates.  360 
 361 
Visual and quantitative analysis of Golgi redistribution around Chlamydia 362 
inclusions 363 
Imaging. HeLa and A549 cells grown on glass coverslips were infected with 364 
Chlamydia strains at MOIs of 0.8. At 26 hpi, cells were fixed with pre-warmed (37°C) 365 
3% formaldehyde in PBS for 20 minutes at room temperature. All washes and 366 
antibody staining’s were performed with pre-warmed (37°C) PBS and antibody 367 
solutions respectively. Fixed cells were stained with rabbit anti-Slc141 and mouse 368 
anti-GM130 antibodies (BD Biosciences), and Hoechst. Z-stacks of stained cells 369 
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were captured on a Zeiss 880 inverted fluorescence microscope with a 63X objective 370 
(Zeiss).  371 
 372 
Golgi redistribution quantification. For each Z-stack, maximum intensity Z-projections 373 
were generated with Image J (NIH). The length of Golgi (defined by GM130 staining) 374 
distributed around Chlamydia inclusions and the length of each inclusion perimeter 375 
(defined by Slc1 staining) were measured using the line tool from Image J (NIH). The 376 
ratio of Golgi length to inclusion perimeter length was determined, and values are 377 
expressed as a percent. Three independent experiments were performed to assess 378 
Golgi distribution. Golgi distribution was assessed from 6 fields for a total of 90 cells 379 
per independent experiment.  380 
 381 
High-resolution imaging. Standard deviation Z-projections of captured images (see 382 
above) were generated and images minimally processed with Image J (NIH). 383 
 384 
ChlaDUB expression in mammalian cells 385 
Imaging. HeLa cells grown on glass coverslips were transfected with 1 µg of plasmid 386 
using Genejuice (EMD Millipore). At 23-hours post-transfection, cells were fixed with 387 
4% paraformaldehyde, immunostained for GM130 (BD Biosciences 610822). Nucleic 388 
acids were stained with DAPI. Images were collected on a Nikon Eclipse Ti 389 
microscope with a Super Plan Fluor ELWD 40XC objective or a 3i Marianas spinning 390 
disk inverted confocal microscope with a 63X oil objective and a CMOS camera 391 
(Hamatsu). The images were then processed using SlideBook software and 392 
Photoshop CS4 Version 11.0 (Adobe). 393 
 394 
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Quantification of Golgi fragmentation. Images were converted from 16-bit to 8-bit 395 
binary using Fiji. Following selection of the region of interest, the number and surface 396 
area of Golgi-stained particles were quantified using the Analyze Particles tool of Fiji. 397 
A minimum of three independent experiments were performed to assess Golgi 398 
fragmentation, each consisting of ~65 counted cells. Multinucleated cells, as well as 399 
cells that were cycling through mitosis, were excluded from the analysis.  400 
 401 
Western blotting. HeLa cells were transfected with 1 µg of plasmid using Genejuice 402 
(EMD Millipore). At 23-hours post-transfection, cells were lysed in RIPA buffer and 403 
the protein amount was assessed using the Pierce BCA Protein Assay Kit (Thermo). 404 
20 µg of lysates were resolved by SDS-PAGE and transferred onto nitrocellulose. 405 
Membranes were blocked in 5% milk/TBST for 1 h and probed for GFP (sheep, 406 
1:1000, made in-house) and actin (rabbit, 1:10,000, Sigma A2266) for 1 h at room 407 
temperature. The IRDye 680LT Donkey anti-Rabbit IgG (LI-COR 926-68023) and 408 
IRDye 800CW Donkey anti-Goat IgG (cross-reacts with sheep IgG, LI-COR 926-409 
32214) secondary antibodies were used at a concentration of 1:10,000 in 5% milk. 410 
Membranes were scanned using a LI-COR CLx Odyssey system and the Image 411 
Studio software, and minimally processed in Photoshop CS4 Version 11.0 (Adobe). 412 
 413 
Statistics. All statistical analyses were performed using GraphPad Prism 7.0. 414 
Chlamydia growth assays were analyzed using a two-tailed Welch’s t-test, all other 415 
analyses used a two-tailed Mann-Whitney test. All experiments contained three 416 
biological replicates. Data from these replicates is either combined or plotted 417 
separately, as described in the figure legends. 418 
 419 
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Data availability. The data that support the findings in this study are available from 420 
the corresponding author upon request. Coordinates and structure factors for the 421 
ChlaDUB1~Ub, ChlaDUB1~CoA, and C.a. ChlaDUB structures have been deposited 422 
with the protein data bank accession codes 6GZS, 6GZT, and 6GZU respectively.  423 
 424 
 425 
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Figure 1: Identification of specialized and dual-function CE-clan enzymes 600 
a) Panel of purified bacterial CE-clan enzymes and their catalytically inactive Cys-to-601 
Ala mutants. b) Deubiquitinase assay monitoring cleavage of K63-linked diUb 602 
following overnight incubation. c) Acetyltransferase assay monitoring 14C 603 
incorporation following a 2 h incubation of each protein with 14C-labeled Acetyl-CoA. 604 
Below, histogram representation of the WT/CA 14C incorporation ratio following 605 
normalization of the 14C autoradiography signal to the Coomassie stain. The average 606 
of three replicate experiments is plotted. A WT/CA ratio of one indicates no AcT 607 
activity, and is denoted by a red dashed line. Gels in a, b, and c are representative of 608 
triplicate experiments. All uncropped gels are shown in Supplementary Fig. 10. 609 
Asterisks indicate appreciable DUB (b) or AcT (c) activity. d) ChlaDUB1 complex 610 
crystal structures that capture intermediate stages of deubiquitinase (top) and 611 
acetyltransferase (bottom) activities. Inlay, a representative view of the ChlaDUB1 612 





Figure 2: Molecular dissection of dual deubiquitinase/acetyltransferase 617 
activities 618 
a) Close-up of the ChlaDUB1:CoA (brown:green) and ChlaDUB1:Ub (tan:red) 619 
interfaces with key interacting residues shown in ball-and-stick. Hydrogen bonds are 620 
shown as dashed lines. b) Helical wheel diagram illustrating the amphipathic nature 621 
of the ChlaDUB1 VR-3 helix, and its interactions with Ub or CoA (colored in red and 622 
green, respectively). c) Deubiquitinase (top) and acetyltransferase (bottom) assays 623 
illustrating that while both activities require the catalytic Cys residue, mutations in the 624 
Ub-binding and CoA-binding regions separate the two functions. A representative gel 625 
is shown of triplicate experiments. d) Sequence alignment of the VR-3 helix for 626 
orthologous Chlamydia ChlaDUB enzymes. The catalytic His, CoA-binding (green) 627 
and Ub-binding (red) residues are marked, and additional contacts are listed. e) 14C 628 
acetylation assay with the ChlaDUB orthologues from C. trachomatis (C.t. 629 
ChlaDUB2) and C. abortus (C.a. ChlaDUB). f) Deubiquitinase assay monitoring K63-630 
linked diUb cleavage by the Chlamydia ChlaDUB orthologues. Gels in e and f are 631 
representative of triplicate experiments. All uncropped gels are shown in 632 
Supplementary Fig. 10. g) Schematic depicting how deubiquitinase and 633 
acetyltransferase functions can be separated either by structure-guided mutation or 634 
evolution as represented by the ChlaDUB orthologues. 635 
 636 
  637 
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Figure 3: ChlaDUB function is required for C. trachomatis Golgi fragmentation 638 
a) Topology diagram illustrating C.t. ChlaDUB1 and C.t. ChlaDUB2 domain 639 
architecture, with active site residues annotated within the catalytic domains. 640 
Changes present in the cdu1-Tn and Cdu2-H203Y defective strains are shown 641 
above. b) C. trachomatis growth assay measured as inclusion forming units (IFU) 642 
output per IFU input following a 48 h infection in either HeLa or A549 cells. Values 643 
were normalized to 100% for wild-type. Statistical significance compared to parental 644 
controls was measured using a two-tailed Welch’s t-test. HeLa: Wild-type – cdu1-Tn, 645 
p=0.768; RifR – Cdu2-H203Y, p=0.0195; SpecR – Cdu2-H203Y, p=0.392. A549: Wild-646 
type – cdu1-Tn, p=0.000173; RifR – Cdu2-H203Y, p=0.615; SpecR – Cdu2-H203Y, 647 
p=0.791. n=3. c) Representative confocal images showing Golgi fragmentation and 648 
redistribution around the Chlamydia inclusion following a 26 h infection of HeLa cells. 649 
Samples were immunostained with anti-GM130 (cis-Golgi, red) and anti-Slc1 650 
(Chlamydia, green) antibodies, and Hoechst stained (DNA, blue). Isolated channels 651 
for the boxed region are shown below, and full versions are shown in Supplementary 652 
Fig. 6b. Scale bar corresponds to 10 µm. d) As in c) for A549 cells. Full versions are 653 
shown in Supplementary Fig. 6c. e) Quantification of c) following measurement of 654 
Golgi distribution around the circumference of the Chlamydia inclusion in 90 cells for 655 
each of three independent replicates. Mean values are shown as a red bar with 656 
individual data points overlaid. Statistical significance compared to parental was 657 
measured using a two-tailed Mann-Whitney test. Wild-type – cdu1-Tn, p<1E-15; RifR 658 
– Cdu2-H203Y, p<1E-15; SpecR – Cdu2-H203Y, p<1E-15. Separated plots for each 659 
replicate are shown in Supplementary Fig. 6d. f) As in e) for A549 cells. Wild-type – 660 
cdu1-Tn, p<1E-15; RifR – Cdu2-H203Y, p<1E-15; SpecR – Cdu2-H203Y, p<1E-15. 661 
Separated plots for each replicate are shown in Supplementary Fig. 6e. 662 
 30 
Figure 4: ChlaDUB deubiquitinase activity is required for C. trachomatis Golgi 663 
fragmentation 664 
a) Topology diagram illustrating the constructs used to characterize activity 665 
dependence of Golgi fragmentation following expression of ChlaDUB1 in mammalian 666 
cells. Separation-of-function mutations were selected from structural and biochemical 667 
work discussed in Fig. 2. b) Representative confocal images showing Golgi 668 
fragmentation in HeLa cells following expression of GFP-tagged ChlaDUB1. Samples 669 
were immunostained with anti-GM130 (cis-Golgi, red) and DAPI stained (DNA, blue). 670 
GFP fluorescence is shown in green. Isolated channels for the boxed region are 671 
shown below, and full versions are shown in Supplementary Fig. 7b. Scale bar 672 
corresponds to 10 µm. c) Quantification of cis-Golgi-stained puncta from b) for ~65 673 
cells in each of three independent replicates (two remaining replicates are plotted in 674 
Supplementary Fig. 7c). Mean values are shown as red bars with individual data 675 
points overlaid. Statistical significance compared to GFP control was measured using 676 
a two-tailed Mann-Whitney test. GFP – WT, p=2.53E-8; GFP – C345A, p=0.386; 677 
GFP – I267R, p=0.0253; GFP – K268E, p=2E-15. d) Measurement of cis-Golgi-678 
stained puncta size from b) for ~65 cells in each of three independent replicates (two 679 
remaining replicates are plotted in Supplementary Fig. 7d). Mean values are shown 680 
as red bars, median values are shown as black bars inside a quartile box plot, with 681 
individual data points overlaid. Statistical significance compared to GFP control was 682 
measured using a two-tailed Mann-Whitney test. GFP – WT, p=6.26E-12; GFP – 683 
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Supplementary Figure 1: Identification of specialized and dual-function CE-clan 
enzymes 
a) Extended time course following ChlaDUB1 acetyltransferase activity. Right, 14C 
incorporation normalized to Coomassie stain, plotted over time. b) As in a), for GST-
YopJ and substrate MEK2 in the absence and presence of activator IP6. c) As in a), 
for AvrA in the absence and presence of activator IP6. Full time course experiments 
shown in a,b,c were performed once but are representative of smaller scale 
experiments performed in triplicate. d) Anti-Acetyl-lysine Western blot analysis of 
ChlaDUB1 acetylation activity following overnight incubation with Acetyl-CoA. A 
representative gel is shown of duplicate experiments. e) 2 h incubation of ChlaDUB1 
with 14C Acetyl-CoA (0’), followed by 1 h incubation with H2O, lysine deacetylase 
SIRT1, base (100 mM hydroxylamine in 100 mM bicine pH 9.0), or acid (1% formic 
acid). The histogram below plots the 14C autoradiography signal normalized to the 
Coomassie stain as a difference compared to the 0’ sample. Individual values and 
the average are shown. A representative gel is shown of triplicate experiments. f) 
Acetyltransferase assay testing the effect of YopJ/AvrA activator IP6 on ChlaDUB1 
activity. The histogram below plots the 14C autoradiography signal normalized to the 
Coomassie stain as a difference compared to the sample containing IP6. Individual 
values and the average are shown. A representative gel is shown of triplicate 
experiments. All uncropped gels are shown in Supplementary Fig. 10. g) Electrostatic 
surface potential (blue, positive charge; red, negative charge) showing the IP6 
binding site on HopZ1a (pdb id 5KLQ) and the analogous region of ChlaDUB1 (pdb 
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Supplementary Figure 2: Visualization and characterization of ChlaDUB1 dual 
activity 
a) Superposition of the apo ChlaDUB1 (pdb id 5HAG), ChlaDUB1~Ub complex, and 
ChlaDUB1~CoA crystal structures showing only a slight movement (≤3Å Ca) in the 
VR-3 helix. 2|Fo|-|Fc| electron density contoured at 1σ is shown around the Ub C-
terminus in the ChlaDUB1~Ub structure and around CoA of the ChlaDUB1~CoA 
structure. b) Full ASU of the 1.9Å ChlaDUB1~Ub structure showing 2|Fo|-|Fc| 
electron density contoured at 1σ c) Comparison of the ChlaDUB1~Ub complex to the 
eukaryotic SENP2-SUMO2 (pdb id 2IO0) and NEDP1~NEDD8 (pdb id 2BKR) 
complexes. The complex structures are aligned based upon the protease catalytic 
triad; only the conserved catalytic cores of SENP2 and NEDP1 are shown for clarity. 
d) Comparison of the ChlaDUB1~Ub complex to other bacterial DUB complexes, 
XopD~Ub (pdb id 5JP3) and SdeA~Ub (pdb id 5CRA). The complex structures are 
aligned based upon the protease catalytic triad; only the conserved catalytic cores of 
XopD and SdeA are shown for clarity. e) |Fo|-|Fc| omit map density (green, 2.5σ) for 
the CoA binding site in the 2.1Å ChlaDUB1~CoA crystal structure. f) Electrostatic 
surface potential (blue, positive charge; red, negative charge) illustrating charge 
complementarity within the CoA binding site. g) Comparison of the ChlaDUB1~CoA 
complex with the YopJ-like acetyltransferase HopZ1a~CoA (pdb id 5KLQ), and the 
human (pdb id 2PFR) and Mycobacterium marinum (pdb id 2VFC) arylamine N-
acetyltransferases (NATs), aligned via their catalytic triads. h) CoA molecules from 
the structures shown in g) superposed onto the ChlaDUB1~CoA crystal structure. i) 
Secondary structure diagram illustrating the variable regions unique to ChlaDUB1, 





















































































































Supplementary Figure 3: Reaction schematic for ChlaDUB1 DUB and AcT 
activities 
Proposed reaction scheme illustrating how ChlaDUB1 could mediate key steps for 
deubiquitination (left) and acetylation (right), including i) nucleophilic attack, ii) the 
acyl-enzyme intermediate, and iii) resolution back to the apo enzyme following attack 
by water (DUB) or substrate Lys (AcT). States outlined in black correspond to the 















































Supplementary Figure 4: DUB and AcT requirements in the ChlaDUB1 active 
site 
a) K63-linked diUb deubiquitinase assay showing a dependence upon the ChlaDUB1 
catalytic Cys (C345), general base His (H275), and oxyanion hole Gln (Q338). A 
representative gel is shown of triplicate experiments. b) As in a), for a 14C acetylation 
assay. A representative gel is shown of triplicate experiments. c) ChlaDUB1 
acetylation assay in the presence of increasing concentrations of wild-type Ub (aa 1-
76) or Ub∆C (aa 1-72). A representative gel is shown of duplicate experiments. All 





































Supplementary Figure 4: DUB and AcT requiremens in the ChlaDUB1 active site
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Supplementary Figure 5: Molecular dissection of dual 
deubiquitinase/acetyltransferase activities 
a) Cleavage of the KG-TAMRA-linked Ub substrate by wild-type and mutant 
ChlaDUB1 monitored by change in fluorescence polarization over time. b) 
Deubiquitinase assay comparing C.t. ChlaDUB1 activity against C.t. ChlaDUB2 and 
C.a. ChlaDUB. Enzyme concentrations were adjusted to produce qualitatively similar 
rates of cleavage. Uncropped gels are shown in Supplementary Fig. 10. c) 
Comparison of activity and specificity for C.t. ChlaDUB1, C.t. ChlaDUB2, and C.a. 
ChlaDUB using the KG-TAMRA-linked Ub/Ubl substrates. All enzymes were held at a 
high concentration to illustrate differences in cleavage rates. Data in a,b,c are 
representative of assays performed in triplicate. d) 1.5 Å crystal structure of C.a. 
ChlaDUB with active site residues shown in ball-and-stick. The structure revealed an 
unexpected His-Cys-His-Cys Zn2+ binding site located in VR-2. Any significance of 
this metal binding beyond a structural role is unknown. Inlay, close-up view showing 
Zn2+-coordinating residues, along with 2|Fo|-|Fc| electron density contoured at 1σ. 
Right, secondary structure diagram illustrating the variable regions unique to C.a. 
ChlaDUB, and their contributions to the CoA S1’ site (green). Structure boundaries 
are annotated. e) Sequence alignment of Chlamydia ChlaDUB orthologues focusing 
on the region surrounding the C.a. ChlaDUB Zn2+-binding site. ChlaDUB orthologues 
roughly segregate into three groups: 1) ChlaDUB1 members that lack any apparent 
Zn2+-coordinating residues, 2) ChlaDUB2 members that encode a conserved set of 
four, potentially Zn2+-coordinating Cys residues (grey arrows), and 3) ChlaDUB 
members that encode a conserved HCHC Zn2+-binding motif as observed in C.a. 
ChlaDUB (red arrows). Numbering corresponds to the C.t. ChlaDUB1 sequence. 
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Supplementary Figure 6: ChlaDUB deubiquitinase activity is required for C. 
trachomatis Golgi fragmentation 
a) Deubiquitinase assay comparing the activities of wild-type and H203Y ChlaDUB2 
against K63-linked diUb. A representative gel is shown of triplicate experiments. 
Uncropped gels are shown in Supplementary Fig. 10. b) Representative confocal 
images showing Golgi fragmentation and redistribution around the Chlamydia 
inclusion following infection of HeLa cells. Samples were immunostained with anti-
GM130 (cis-Golgi, red) and anti-Slc1 (Chlamydia, green) antibodies, and Hoechst 
stained (DNA, blue). Scale bar corresponds to 10 µm. c) As in b) for A549 cells. d) 
Quantification of Golgi fragmentation, as shown in Fig. 3e, for individual biological 
replicates. Mean values are shown as a red bar with individual data points overlaid. 
e) As in d) for A549 cells. 
 
  
Supplementary Figure 6:  ChlaDUB function is required for C. trachomatis Golgi fragmentation



















































HeLa (Replicate 1) HeLa (Replicate 2) HeLa (Replicate 3)


































































































































































































































































Supplementary Figure 7: ChlaDUB1 deubiquitinase activity is required for C. 
trachomatis Golgi fragmentation 
a) Anti-GFP Western blot illustrating equal expression of GFP-ChlaDUB1 wild-type 
and point mutants. The inactive ChlaDUB1 C345A appears to be mono-ubiquitinated. 
A representative blot is shown of duplicate experiments. Uncropped gels are shown 
in Supplementary Fig. 10. b) Representative confocal images showing Golgi 
fragmentation in HeLa cells following expression of GFP-tagged ChlaDUB1. Samples 
were immunostained with anti-GM130 (cis-Golgi, red) and DAPI stained (DNA, blue). 
GFP fluorescence is shown in green. Scale bar corresponds to 10 µm. c) 
Quantification of Golgi puncta, as in Fig. 4c, for additional two biological replicates. 
Mean values are shown as red bars with individual data points overlaid. Statistical 
significance compared to GFP control was measured using a two-tailed Mann-
Whitney test. Replicate 2: GFP – WT, p=9.40E-9; GFP – C345A, p=0.256; GFP – 
I267R, p=0.958; GFP – K268E, p=4.29E-6. Replicate 3: GFP – WT, p=1.0E-14; GFP 
– C345A, p=0.579; GFP – I267R, p=0.0276; GFP – K268E, p=5.07E-7. d) 
Quantification of Golgi puncta size, as in Fig. 4d, for additional two biological 
replicates. Mean values are shown as red bars, median values are shown as black 
bars inside a quartile box plot, with individual data points overlaid. Statistical 
significance compared to GFP control was measured using a two-tailed Mann-
Whitney test. Replicate 2: GFP – WT, p<1E-15; GFP – C345A, p=0.655; GFP – 
I267R, p=0.863; GFP – K268E, p=0.000131. Replicate 3: GFP – WT, p<1E-15; GFP 



















































































































































































Supplementary Figure 8: ChlaDUB2 deubiquitinase activity is required for C. 
trachomatis Golgi fragmentation. 
a) Anti-GFP Western blot illustrating equal expression of GFP-ChlaDUB2 wild-type 
and point mutants. The inactive ChlaDUB2 C282A appears to be mono-ubiquitinated. 
A representative blot is shown of duplicate experiments. Uncropped gels are shown 
in Supplementary Fig. 10. b) Representative confocal images of experiments 
performed in triplicate showing Golgi fragmentation in HeLa cells following 
expression of GFP-tagged ChlaDUB2. Samples were immunostained with anti-
GM130 (cis-Golgi, red) and DAPI stained (DNA, blue). GFP fluorescence is shown in 
green. Scale bar corresponds to 10 µm. c) Quantification of Golgi puncta, as in Fig. 
4c, for all three biological replicates of ChlaDUB2 expression. Mean values are 
shown as red bars with individual data points overlaid. Statistical significance 
compared to GFP control was measured using a two-tailed Mann-Whitney test. GFP 
– WT, p=0.00239; GFP – C282A, p=0.0660; GFP – H203Y, p=0.102. d) 
Quantification of Golgi puncta size, as in Fig. 4d, for all three biological replicates of 
ChlaDUB2 expression. Mean values are shown as red bars, median values are 
shown as black bars inside a quartile box plot, with individual data points overlaid. 
Statistical significance compared to GFP control was measured using a two-tailed 
Mann-Whitney test. GFP – WT, p=1.95E-6; GFP – C282A, p=2.98E-12; GFP – 
H203Y, p=3.16E-7. e) Representative images of experiments performed in triplicate 
demonstrating co-localization of ChlaDUB2 constructs with a mCherry-KDL reporter 
of the ER. 
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Supplementary Figure 9: ChlaDUB1 DUB activity in the context of Chlamydia 
infection 
Illustration of ChlaDUB1 dual activity in the context of Chlamydia infection. At 
approximately 20 hours post infection, the Chlamydia inclusion has re-localized to the 
microtubule-organizing center, where active bacterial replication begins. At this time, 
ChlaDUB1 and ChlaDUB2 are expressed and secreted into the host cell, where they 
insert into the inclusion membrane15,27. The DUB activities of both ChlaDUB effector 
proteins is required for fragmentation of the host Golgi apparatus (shown herein), 
which redistributes around the inclusion to facilitate Chlamydia replication24. InaC, 
another Chlamydia effector localized to the outside of the inclusion, recruits host 14-
3-3 proteins and ADP ribosylation factors (ARFs)23 to promote Golgi redistribution 
around the inclusion by stabilizing the surrounding microtubule network through 
alpha-tubulin detyrosination and acetylation26. Host GTPases Rab6A and Rab11A 
are also recruited to the Chlamydia inclusion to regulate Golgi fragmentation27, but 
how they are recruited and the role they play upon arrival remain to be determined. 
Targets of the ChlaDUB1 AcT activity and their contributions to Chlamydia biology 
also remain unknown, though ChlaDUB1 has been implicated in other host 
processes such as suppression of NF-kB signaling13 and cell death15, and the activity 
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Supplementary Figure 10:  Uncropped gels
Main Figures
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ChlaDUB1~Ub ChlaDUB1~CoA C.a. ChlaDUB 
Data collection     
Space group P 21 P 21 I 2 3 P 1 
Cell dimensions     








    a, b, g  (°) 90, 95.6, 90 90, 93.57, 90 90, 90, 90 94.72, 102.17, 
101.23 
Wavelength (Å) 0.9798 (peak)    








Rmerge 0.064 (1.0) 0.043 (0.476) 0.085 (0.653) 0.063 (0.471) 
I / sI 24.3 (3.0) 12.4 (2.4) 10.3 (2.1) 8.4 (2.0) 
Completeness (%) 100.0 (100.0) 99.9 (100.0) 99.9 (100.0) 96.4 (94.2) 
Redundancy 17.1 (17.5) 3.4 (3.4) 5.1 (5.2) 3.6 (3.7) 
     
Refinement     
Resolution (Å)  26.85-1.90 66.32-2.10 42.86-1.47 
No. reflections  93418 116341 162381 
Rwork / Rfree  18.1 / 21.3 18.2 / 21.6 15.2 / 18.2 
No. atoms     
    Protein  2515 2140 1937 
    Ligand/ion  15 77 7 
    Water  184 147 192 
B-factors     
    Protein  60.7 29.2 30.4 
    Ligand/ion  66.4 54.2 39.7 
    Water  48.7 36.2 41.1 
R.m.s. deviations     
    Bond lengths (Å)  0.010 0.011 0.014 
    Bond angles (°)  1.38 1.12 1.56 
One crystal was used per data collection. *Values in parentheses are for highest-resolution shell. 
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     Reference 
strain 
cdu1-Tn CTL0247 cdu1  
 
ChlaDUB1/Cdu1   
 
Y297* Fischer et 
al., 201715 
RifR LGV 
L2 434 Bu 











CTL0246 cdu2 ChlaDUB2/Cdu2 G607A H203Y This study 




Supplementary Table 3: M467 rs22 single nucleotide variants 
 
a) Single nucleotide variants (SNVs) present in M467 rs22 parental strain 












303169 CTL0246 cdu2 Non synonymous G607A H203Y 
79831 CTL0066 nth Non synonymous G463A L155F 
214963 CTL0166 pgsA Synonymous G345A   
33473 CTL0027 sfhB Non synonymous C191T S64F 
55081     Non coding G55081A   
142623     Non coding G142623A   
Variants identified by whole genome sequencing. 
 













303169 CTL0246 cdu2 Non synonymous G607A H203Y 
Variants identified by PCR based genotyping. 
 
 
 
